Sign in

CIK 0001157601 · Large accelerated filer

MADRIGAL PHARMACEUTICALS, INC.

Sign in to watch
Ticker
MDGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
(267) 824-2827
Business address
1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
Former names
MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
  1. 4 Open-market sale Director sold 491 shares at $431.94 ($212,083)
  2. 4 Grant or award Chief Medical Officer acquired 4,374 shares (grant or award)
  3. 4 Open-market sale EVP and CFO sold 1,183 shares at $427.21 ($505,389)
  4. 4 Option exercise Director acquired 2,500 shares (option exercise)
  5. 4 Option exercise Director acquired 4,000 shares (option exercise)
  6. 4 Planned sale Chief Commercial Officer sold 910 shares at an average $493.78 ($449,339)
  7. 4 Open-market sale President and CEO sold 1,577 shares at $492.42 ($776,546)
  8. 4 Open-market sale Director sold 647 shares at $492.42 ($318,596)
  9. 4 Planned sale General Counsel sold 692 shares at an average $497.36 ($344,173)
  10. 4 Open-market sale Director sold 2,238 shares at $490.77 ($1,098,343)
  11. 4 Grant or award Chief Accounting Officer acquired 2,398 shares (grant or award)
  12. 3 Insider Initial Statement of Ownership
  13. 4 Planned sale Director sold 280 shares at $551.24 ($154,348)
  14. 4 Planned sale Director sold 24,520 shares at an average $522.39 ($12,808,957)
  15. 4 Planned sale Director sold 240 shares at an average $550.33 ($132,080)
  16. 4 Planned sale Director sold 18,410 shares at an average $522.40 ($9,617,312)
  17. 4 Planned sale Director sold 24,800 shares at an average $552.18 ($13,694,158)
  18. 4 Planned sale Director sold 18,650 shares at an average $552.15 ($10,297,573)
  19. 4 Open-market sale President and CEO sold 2,400 shares at $575.34 ($1,380,816)
  20. 4 Planned sale EVP and CFO sold 4,173 shares at an average $578.34 ($2,413,416)

Page 2 of 29 · 564 filings